MINI REVIEW

Sacubitril/valsartan, sodium-glucose cotransporter 2 inhibitors and vericiguat for congestive heart failure therapy

Tobias Norre1 | Daniela Grimm1,2 | Ulf Simonsen1

1Department of Biomedicine, Aarhus University, Aarhus, Denmark
2Department of Microgravity and Translational Regenerative Medicine, Clinic for Plastic, Aesthetic and Hand Surgery, Otto-von-Guericke-University Magdeburg, Magdeburg, Germany

Correspondence
Professor Ulf Simonsen, Department of Biomedicine, Aarhus University, Ole Worms Allé 4, 8000 Aarhus C, Denmark.
Email: us@biomed.au.dk

Funding information
Novo Nordisk Foundation, Grant/Award Number: NNF20OC0065767

Abstract
Heart failure is associated with notable morbidity and mortality, and therefore, novel therapies are needed. This minireview focused on the effects and mechanisms of action of sacubitril/valsartan, sodium-glucose cotransporter 2 inhibitors and vericiguat in heart failure patients. A systematic review of the current literature was conducted. Seventeen randomised clinical trials regarding the effects of these drug classes were included. The mechanism of action of each treatment could improve pathophysiological imbalances present in heart failure. All three drug classes revealed a reduction in hospitalisations for heart failure or death from cardiovascular causes in patients with reduced ejection fraction. Sacubitril/valsartan also reduced hospitalisations and death from cardiovascular causes in patients with mid-range ejection fraction, but not in patients with preserved ejection fraction. The sodium-glucose cotransporter 2 inhibitors, sotagliflozin and empagliflozin, reduced hospitalisations and death from cardiovascular causes in heart failure patients with preserved ejection fraction. None of the three drug classes was associated with a higher prevalence of treatment discontinuation due to increases in adverse effects in large-scale randomised clinical trials compared with placebo. Further studies are required to clarify the extent of effects of these medications in different subpopulations—especially in patients with mid-range and preserved ejection fraction.

KEYWORDS
clinical trials, heart failure, sacubitril/valsartan, sodium-glucose cotransporter 2 inhibitors, vericiguat

INTRODUCTION

Congestive heart failure is a clinical syndrome characterised by fatigue, dyspnoea and symptoms of stasis caused by dysfunction of the left ventricle. Traditionally, congestive heart failure is classified into two categories—heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF). Patients with HFrEF have a reduced left ventricular ejection fraction (LVEF) ≤ 40% and...
patients with HFrEF have LVEF ≥ 50%. A third group, heart failure with mid-range ejection fraction (HFmrEF) with LVEF 41%–49%, has been introduced in recent years.1

In HFrEF, angiotensin-converting enzyme inhibitors (ACEi),2,3 angiotensin II type 1 (AT1) receptor antagonists,4,5 beta-adrenergic antagonists (BAAs)6-8 and mineralocorticoid receptor antagonists (MRAs)9,10 had shown to reduce mortality and morbidity and had been the mainstay of treatment for symptomatic HFrEF. In recent years, sacubitril/valsartan11 and sodium-glucose cotransporter 2 inhibitors (SGLT2i)12,13 demonstrated to reduce mortality and morbidity, and they are now new recommended treatment options for symptomatic HFrEF according to the recommendations from the American College of Cardiology (ACC), the European Society of Cardiology (ESC) and the Danish Society of Cardiology (DCS).1,14,15

At the time of ESC guideline publication, no pharmacological treatment had demonstrated to reduce mortality and morbidity in HFpEF. Clinical trials have investigated the effect of ACEi,16 BAAs,17 AT1 receptor antagonists,18,19 MRAs20 and calcium-channel blockers21 without showing any significant effect. This reflects the recommendations from ACC, ESC and DCS. They recommend treating comorbidities such as hypertension and symptoms of stasis but do not include any mortality-reducing drugs.1,15,22

HFrEF and HFpEF are associated with notable morbidity and mortality. Consequently, it is essential to find novel therapies for these patients.23,24 Three novel treatment modalities including sacubitril/valsartan, SGLT2i and vericiguat are currently under investigation in clinical trials for the treatment of heart failure.

Sacubitril/valsartan is a neprilysin inhibitor prodrug combined with an AT1 receptor antagonist (see Figure 1). The prodrug sacubitril is metabolised to the active neprilysin inhibitor.25 Neprilysin inactivates with varying relative affinities among different substrates: Its highest affinity is for atrial natriuretic peptide, C-type natriuretic peptide and angiotensin I and II, whereas its lowest affinity is for B-type natriuretic peptide, endothelin-1 and bradykinin.26 Hence, the inhibition of neprilysin causes levels of natriuretic peptides to rise.27 Natriuretic peptides stimulate myocardial relaxation and reduce myocardial fibrosis. In the kidneys, they have a diuretic and natriuretic effect. In blood vessels, natriuretic peptides cause vasodilation.28,29 The inhibitory effect on neprilysin combined with the angiotensin receptor II antagonism by valsartan results in a more pronounced reduction in blood pressure compared with valsartan alone.30

According to the US Food and Drug Administration (FDA), adverse effects (AEs) of sacubitril/valsartan include hypotension, hyperkalaemia, cough, impaired renal function, angioedema and foetal toxicity.31 Sacubitril/valsartan has not been associated with a higher risk of treatment discontinuation due to AEs compared with placebo in heart failure therapy.11,32

SGLT2i have been developed for glycaemic control in diabetes mellitus. SGLT2i inhibit the reabsorption of sodium and glucose in the proximal tubule. The inhibition of sodium-glucose cotransporter 2 (SGLT2) leads to an increase in urinary sodium and glucose excretion, which results in a decrease in blood pressure.33,34 The predominant diuretic effect is due to increased sodium excretion and fluid volume reduction.35,36 The renin-angiotensin-aldosterone system (RAAS) inhibition by SGLT2i has been shown to reduce systemic blood pressure.37-41}

FIGURE 1  Mechanism of action of SGLT2 inhibitors, sacubitril/valsartan and vericiguat in congestive heart failure. cGMP, cyclic guanosine monophosphate; NO, nitric oxide; sGC, soluble guanylate cyclase; SGLT2, sodium-glucose cotransporter 2
sodium and glucose in the proximal tubule of the kidney (see Figure 1). SGLT2i exert a significant effect on the risk of heart failure in patients with type 2 diabetes.\textsuperscript{33} Besides lowering blood glucose levels, SGLT2i have a diuretic effect caused by osmotic diuresis.\textsuperscript{34} This diuretic effect leads to a decrease in systolic blood pressure.\textsuperscript{35} The combination of osmotic diuresis by glucose and sodium may cause a higher degree of loss of interstitial fluid compared with conventional diuretics, which diuretic effect primarily relies on sodium.\textsuperscript{36,37} SGLT2i resulted in lowering of the lung fluid volumes and lowering of left ventricle end-diastolic and end-systolic volumes compared with placebo.\textsuperscript{38,39} The SGLT2i class includes the drugs canagliflozin, dapagliflozin, empagliflozin, ertugliflozin and sotagliflozin.

According to the FDA, AEs include genital mycotic infections, urinary tract infections, hypotension, impaired renal function, necrotising fasciitis, hypoglycaemia (in diabetes mellitus) and ketoacidosis (in diabetes mellitus).\textsuperscript{40–42} SGLT2i have not been associated with a higher risk of treatment discontinuation due to AEs compared with placebo in heart failure therapy.\textsuperscript{12,13,43} Vericiguat is a soluble guanylate cyclase (sGC) stimulator (see Figure 1). It stimulates the sGC to produce cyclic guanosine monophosphate (cGMP) both directly and by sensitising the sGC to nitric oxide (NO).\textsuperscript{44} This NO–sGC–cGMP pathway is dysregulated in heart failure.\textsuperscript{45} The NO–sGC–cGMP pathway is thought to play a role in vascular smooth muscles and myocardium.\textsuperscript{46} In vascular smooth muscles, this pathway results in relaxation, which can reduce afterload and increase the blood flow to the myocardium and the kidneys to prevent the cardiorenal syndrome.\textsuperscript{47,48}

According to the FDA, AEs include hypotension and anaemia.\textsuperscript{49} Vericiguat has not been associated with a higher risk of treatment discontinuation due to AEs compared with placebo in heart failure therapy.\textsuperscript{50} The three drug classes have recently been reviewed.\textsuperscript{51–53} They exert different mechanisms of action. In order to discuss the effects of the three drug classes, we performed a systematic minireview of randomised controlled trials (RCTs) where sacubitril/valsartan, SGLT2i or vericiguat was applied as treatment.

\section*{2 | MATERIALS AND METHODS}

The RCTs were found through searches in the databases PubMed, Embase and ClinicalTrials.gov (see Figure 2).

\begin{figure}[h]
\centering
\includegraphics[width=\textwidth]{figure2}
\caption{The search for randomised controlled trials. The first exclusion was based on a read-through of the titles. The second exclusion was based on a read-through of the abstracts. The third exclusion was based on a read-through of the full articles.}
\end{figure}

Pubmed, Embase, and ClinicalTrials.gov search

\begin{itemize}
\item N = 192
\item Patients without heart failure (N = 36)
\item Baseline studies (N = 31)
\item Other treatments (N = 6)
\item Not a randomised controlled trial (N = 18)
\item Translation of original study (N = 1)
\end{itemize}

\begin{itemize}
\item N = 100
\item Irrelevant/non-clinical outcomes (N = 46)
\item Studies of prognostic factors (N = 8)
\end{itemize}

\begin{itemize}
\item N = 46
\end{itemize}

\begin{itemize}
\item Included: N = 17
\item Post-hoc analyses (N = 29)
\end{itemize}
Three searches were performed in PubMed (27 December 2021), Embase (27 December 2021) and ClinicalTrials.gov (27 December 2021). The following inclusion filters were used: ‘Clinical Trial’ and ‘Randomized Controlled Trial’. Search terms were ‘(vericiguat) AND (heart failure)’, ‘(sodium-glucose cotransporter 2 inhibitors) AND (heart failure)’ and ‘(sacubitril/valsartan) AND (heart failure)’.

In total, the search found 11 results, 64 results and 117 results, respectively. Inclusion criteria were randomised controlled studies, patients with heart failure, original studies, clinical outcomes and treatment with sacubitril/valsartan, SGLT2i or vericiguat. Seventeen randomised clinical trials regarding the effects of these drugs were included. The exclusion criteria comprised languages other than English, or studies on cell culture experiments or animals. In addition, systematic reviews, meta-analyses and case reports were not included. Only published articles were reviewed.

Status and NCT numbers of the trials were recruited from ClinicalTrials.gov. Completed studies on vericiguat are as follows: VICTORIA (NCT02861534) and VITALITY-HFpEF (NCT03547583). Completed studies on SGLT2i are as follows: DAPA-HF (NCT03036124), EMPEROR-Reduced (NCT03057977), EMPEROR-Preserved (NCT03057951), DECLARE-TIMI 58 (NCT01730534) and VERTIS CV (NCT1986881). Completed studies on sacubitril/valsartan are as follows: PARAGON-HF (NCT01920711), PARADIGM-HF (NCT01035255) and PIONEER-HF (NCT02554890). Terminated studies on SGLT2i are as follows: SOLOIST-WHF (NCT03521934).

3 | RESULTS
3.1 | Effects on heart failure with reduced ejection fraction

The results from selected RCTs investigating the clinical effect of sacubitril/valsartan, SGLT2i and vericiguat in HFrEF were included (see Table 1) in this minireview. The effects of the three different drug classes will be presented separately.

3.1.1 | Sacubitril/valsartan

The effects of sacubitril/valsartan in HFrEF are known since the PARADIGM-HF trial in 2014. The PARADIGM-HF trial randomised patients to treatment with 200 mg sacubitril/valsartan twice daily or 10 mg enalapril twice daily. The sacubitril/valsartan group experienced fewer hospitalisations for heart failure (HHF) or deaths from cardiovascular causes.11

This effect was significant for the two outcomes separately—HHF (relative risk, RR: 0.79 [95% confidence interval, CI: 0.71–0.89]) and death from cardiovascular causes (RR: 0.80 [95% CI: 0.71–0.89])). Furthermore, the sacubitril/valsartan group revealed a lower risk of death from any cause (RR: 0.84 [95% CI: 0.76–0.93]).11 With respect to AEs, the sacubitril/valsartan group revealed higher proportions of patients with hypotension and non-serious angioedema but lower proportions with renal impairment, hyperkalaemia and cough than the enalapril group.11

3.1.2 | Sodium-glucose cotransporter 2 inhibitors

The effects of SGLT2i in HFrEF were studied intensively in recent years. The EMPEROR-Reduced trial randomised patients to treatment with 10 mg empagliflozin once daily or placebo. The DAPA-HF trial treated patients with HFrEF with 10 mg dapagliflozin once daily or placebo. In both studies, the SGLT2i group experienced fewer HHF or deaths from cardiovascular causes.12,13

In the DAPA-HF trial, this effect was significant for the two outcomes separately—HHF (RR: 0.70 [95% CI: 0.59–0.83]) and death from cardiovascular causes (RR: 0.82 [95% CI: 0.69–0.98]). Furthermore, the dapagliflozin group was at a lower risk of death from any cause (RR: 0.83 [95% CI: 0.71–0.97]).13

In the EMPEROR-Reduced trial, this effect was significant for HHF only (RR: 0.69 [95% CI: 0.59–0.81]), but not for death from cardiovascular causes (RR: 0.92 [95% CI: 0.75–1.12]) or death from any cause (RR: 0.92 [95% CI: 0.77–1.10]).12

The effect on HHF or death from cardiovascular causes was independent of type 2 diabetes. In the DAPA-HF trial, the RRs were 0.75 (95% CI: 0.63–0.90) and 0.73 (95% CI: 0.60–0.88) with and without type 2 diabetes, respectively. In the EMPEROR-Reduced trial, the RRs were 0.72 (95% CI: 0.60–0.87) and 0.78 (95% CI: 0.64–0.97) with and without type 2 diabetes, respectively.12,13

In the EMPEROR-Reduced trial, the subpopulation with LVEF ≥ 30% did not show a lower risk of HHF or death from cardiovascular causes (RR: 0.99 [95% CI: 0.76–1.31]).12

The DECLARE-TIMI 58 trial randomised patients with type 2 diabetes to treatment with 10 mg dapagliflozin or placebo. A subgroup of these patients had HFrEF. The patients with HFrEF treated with
Dapagliflozin had a lower incidence of HHF or deaths from cardiovascular causes. This effect was significant for the two outcomes separately—HHF (RR: 0.64 [95% CI: 0.43–0.95]) and death from cardiovascular causes (RR: 0.55 [95% CI: 0.34–0.90]). Furthermore, the dapagliflozin group was at a lower risk of dying from any cause (RR: 0.59 [95% CI: 0.40–0.88]).

The VERTIS CV trial investigated the effect of 5 or 15 mg ertugliflozin compared with placebo in patients with type 2 diabetes and atherosclerotic cardiovascular disease. A subgroup of these patients had heart failure. In the heart failure subgroup, the ertugliflozin group had a lower incidence of HHF or death from cardiovascular causes (RR: 0.63 [95% CI: 0.44–0.90]).

Focusing on the side effects of empagliflozin in the EMPEROR-Reduced trial, the annual rate of decline in the estimated glomerular filtration rate was lower in the empagliflozin group than in the placebo group. Furthermore, empagliflozin-treated patients showed a lower risk of serious renal outcomes. Uncomplicated genital tract infection was reported more frequently with empagliflozin.

Dapagliflozin (DAPA-HF trial) did not show a higher amount of AEs related to volume depletion, renal dysfunction and hypoglycaemia in comparison with the placebo groups.

In the DECLARE-TIMI 58 trial, fewer patients in the dapagliflozin group compared with the placebo

---

**Table 1** Randomised controlled trials investigating the effect of sacubitril/valsartan, sodium-glucose cotransporter 2 inhibitors and vericiguat therapy in HFrEF

| Trial and drug | Inclusion criteria and number of participants | Intervention | Median duration | RR for HHF or death from cardiovascular causes |
|---------------|---------------------------------------------|--------------|----------------|-----------------------------------------------|
| PARADIGM-HF11 | Sacubitril/valsartan 1. LVEF ≤ 40% 2. NYHA II–IV 3. NT-proBNP > 600 pg/ml or hospitalised within 12 months and NT-proBNP > 400 pg/ml \( N = 8442 \) | 97/103 mg twice daily or enalapril of 10 mg twice daily in addition to recommended therapy | 27 months | RR: 0.80 (95% CI: 0.73–0.87) |
| EMPEROR-Reduced12 | Empagliflozin 1. LVEF ≤ 40% 2. NYHA II–IV 3. HHF within 12 months, NT-proBNP > 1000 pg/ml if LVEF 31%–35%, or >2500 pg/ml if LVEF 36%–40% \( N = 3730 \) | 10 mg once daily or placebo in addition to recommended therapy | 16 months | RR: 0.70 (95% CI: 0.65–0.86) |
| DAPA-HF13 | Dapagliflozin 1. LVEF ≤ 40% 2. NYHA II–IV 3. NT-proBNP > 600 pg/ml or hospitalised within 12 months and NT-proBNP > 400 pg/ml \( N = 4744 \) | 10 mg once daily or placebo in addition to recommended therapy | 18.2 months | RR: 0.75 (95% CI: 0.65–0.85) |
| DECLARE-TIMI 5854 | Dapagliflozin 1. Type 2 diabetes 2. HFrEF (LVEF < 45%) \( N = 671 \) | 10 mg once daily or placebo in addition to recommended therapy | 4.2 years | RR: 0.62 (95% CI: 0.45–0.86) |
| VICTORIA50 | Vericiguat 1. LVEF < 45% 2. NYHA II–IV 3. NT-proBNP > 1000 pg/ml 4. HHF within 6 months or receiving intravenous diuretic therapy within 3 months \( N = 5055 \) | 10 mg once daily or placebo in addition to recommended therapy | 10.8 months | RR: 0.90 (95% CI: 0.82–0.98) |

Abbreviations: CI, confidence interval; HFrEF, heart failure with reduced ejection fraction; HHF, hospitalisations for heart failure; LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA, New York Heart Association; RR, relative risk.
group discontinued the assigned regimen during the course of the trial (8.1% vs. 6.9%), and fewer patients in the dapagliflozin group reported serious AEs (34.1% vs. 36.2%) or had major hypoglycaemia (0.7% vs. 1%), acute kidney injury (1.5% vs. 2%) or bladder cancer (0.3 vs. 0.5%). Diabetic ketoacidosis was more common in the dapagliflozin group (0.3 vs. 0.1%). Genital infections leading to discontinuation and serious AEs were more frequent in the dapagliflozin group, both in men and in women, although genital infections reported as serious adverse events were rare (0.9% vs. 0.1%).

3.1.3 | Vericiguat

The effect of vericiguat in HFrEF was investigated in the VICTORIA trial. The VICTORIA trial randomised patients to treatment with 10 mg vericiguat once daily or placebo. The vericiguat group experienced fewer HHF or deaths from cardiovascular causes.50

The effects for the two outcomes separately were HHF (RR: 0.90 [95% CI: 0.81–1.00]) and death from cardiovascular causes (RR: 0.93 [95% CI: 0.81–1.06]). The vericiguat group did not show a significantly lower death risk from any cause (RR: 0.95 [95% CI: 0.84–1.07]). The subpopulation with LVEF ≥ 40% did not show a lower risk of HHF or death from cardiovascular causes (RR: 1.05 [95% CI: 0.81–1.36]).50

With respect to AEs, symptomatic hypotension was reported in 9.1% of the patients in the vericiguat group and in 7.9% of the patients in the placebo group (p = 0.12). Furthermore, syncope was found in 4.0% of the patients in the vericiguat group and in 3.5% of the patients in the placebo group (p = 0.30).51

3.2 | Effects on heart failure with preserved ejection fraction

The results from the most important RCTs investigating the clinical effects of sacubitril/valsartan, SGLT2i and vericiguat in HFpEF were included (see Table 2). The effects of the three drug classes will be presented separately.

3.2.1 | Sacubitril/valsartan

The effect of sacubitril/valsartan in HFpEF was studied in 2012 in the PARAMOUNT trial. The PARAMOUNT trial randomised patients to treatment with 200 mg sacubitril/valsartan twice daily or 160 mg valsartan twice daily. The sacubitril/valsartan group showed a higher reduction in levels of N-terminal pro-B-type natriuretic peptide (NT-proBNP) after 12 weeks.56

The large-scale PARAGON-HF trial investigated the clinical outcome by randomising patients to treatment with 200 mg sacubitril/valsartan twice daily or 160 mg valsartan twice daily. The incidence of death from cardiovascular causes was 8.5% in the sacubitril–valsartan group and 8.9% in the valsartan group (RR: 0.95 [95% CI: 0.79–1.16]). The sacubitril/valsartan group did not experience significantly fewer HHF from cardiovascular causes compared with the valsartan group (RR: 0.85 [95% CI: 0.72–1.00]).32

In the PARAGON-HF trial, the subpopulation with LVEF ≤ 57% (lower median) had a lower risk of HHF or death from cardiovascular causes (RR: 0.78 [95% CI: 0.64–0.95]). This was not the case for the subpopulation with LVEF > 57% (upper median) (RR: 1.00 [95% CI: 0.81–1.21]).32

With respect to safety, patients in the sacubitril–valsartan group showed a higher incidence of hypotension and angioedema and a lower incidence of hyperkalaemia.32

3.2.2 | Sodium-glucose cotransporter 2 inhibitors

The DECLARE-TIMI 58 trial randomised patients with type 2 diabetes to treatment with 10 mg dapagliflozin once daily or placebo. A subgroup of these patients had HFpEF. The patients with HFpEF treated with dapagliflozin did not show a significantly lower incidence of HHF or deaths from cardiovascular causes. There was no significant effect for the two outcomes separately—HHF (RR: 0.72 [95% CI: 0.50–1.04]) and death from cardiovascular causes (RR: 1.41 [95% CI: 0.93–2.13]).54

The SOLOIST-WHF trial randomised patients with type 2 diabetes and heart failure to treatment with 200 mg sotagliflozin once daily or placebo. The patients with HFpEF receiving sotagliflozin did reveal a significantly lower incidence of HHF or death from cardiovascular causes (RR: 0.48 [95% CI: 0.27–0.86]).43

The EMPEROR-Preserved trial randomised patients to treatment with 10 mg empagliflozin once daily or placebo. The empagliflozin group experienced fewer HHF (407 with empagliflozin and 541 with placebo; RR: 0.73 [95% CI: 0.61–0.88]; p < 0.001) or deaths from cardiovascular causes (RR: 0.79 [95% CI: 0.69–0.90]). This effect was independent of the diabetic status. Reported AEs in the empagliflozin group were uncomplicated genital and urinary tract infections and hypotension.57
3.2.3 | Vericiguat

There are only few studies examining the effect of vericiguat on HFpEF. The VITALITY-HFpEF trial randomised patients to treatment with 15 mg vericiguat once daily, 10 mg vericiguat once daily or placebo. The outcome was a change in points according to KCCQ PLS (Kansas City Cardiomyopathy Questionnaire—Physical Life Status) between baseline and after 24 weeks. Both the 15 mg/day vericiguat group and the 10 mg/day vericiguat group did not show a better score compared with the placebo group. The percentage of patients with AEs was 65.2% in the 15 mg/day vericiguat group, 62.2% in the 10 mg/day vericiguat group and 65.6% in the placebo group. Reported AEs were symptomatic hypotension and syncope.

3.3 | Adverse effects

None of the three drug classes was associated with a higher prevalence of treatment discontinuation due to AEs in large-scale RCTs compared with placebo (see Table 3).
The effect, recommendations and future studies regarding the three novel therapies are discussed for HFrEF, HFpEF and HFmrEF separately.

4.1 | Heart failure with reduced ejection fraction

4.1.1 | Sacubitril/valsartan

In the PARADIGM-HF trial, sacubitril/valsartan was more effective than enalapril in HFrEF with regard to HHF, death from cardiovascular causes and death from any cause.\(^\text{11}\) The effect was also significant in health-related quality of life outcomes.\(^\text{59}\) Post hoc analyses of the PARADIGM-HF trial demonstrated that this superiority to enalapril was independent of age, risk status, reaching target doses, background therapy, blood pressure and aetiology of heart failure.\(^\text{60–65}\) In the PIONEER-HF trial, the superior effect of sacubitril/valsartan to enalapril was also present following acute decompensation.\(^\text{66}\) The LIFE trial did not find a better effect of sacubitril/valsartan compared with valsartan in patients with LVEF ≤ 35% and New York Heart Association (NYHA) IV.\(^\text{67}\)

The ESC and DCS recommend sacubitril/valsartan to replace ACEi in HFrEF after initiation of ACEi, BAA and MRA, if the patient is still symptomatic (NYHA II–IV).\(^\text{1,15}\) The ACC recommends the initiation of sacubitril/valsartan as first treatment without prior treatment with ACEi.\(^\text{14}\)

These recommendations reflect the evidence from the PARADIGM-HF trial (see Table 1). In the TITRATION study, initiation of sacubitril/valsartan without prior ACEi treatment was tolerated as well as the initiation of ACEi.\(^\text{68}\)

4.1.2 | Sodium-glucose cotransporter 2 inhibitors

In both the DAPA-HF trial and the EMPEROR-Reduced trial, SGLT2i showed a better effect than placebo in addition to recommended therapy in HFrEF when it comes to HHF or death from cardiovascular causes.\(^\text{12,13}\) The effect was also significant in health-related quality of life outcomes.\(^\text{72,73}\) Post hoc analyses revealed that the effect was independent of diabetic status, age and sacubitril/valsartan or enalapril treatment.\(^\text{74,75}\) In the EMPEROR-Reduced trial, the subpopulation with LVEF ≥ 30% did not show this effect, but this could be a result of underpoweredness. The DAPA-HF trial showed a significant effect on death from any cause, but the EMPEROR-Reduced trial did not have this effect.\(^\text{12,13}\)

The ESC and DCS recommend considering SGLT2i treatment in patients with HFrEF after initiation of ACEi or sacubitril/valsartan and BAA when the patient is with (1) NYHA II–IV and (2) LVEF ≤ 40%.\(^\text{15}\)

Future trials should investigate the effects in stable patients with lower levels of natriuretic peptides and should be tested as initiation therapy instead of ACEi.

At the moment, the PARALLEL-HF trial examines the effect shown in the PARADIGM-HF trial in a Japanese population.\(^\text{69}\) Currently, sacubitril/valsartan is investigated in other subpopulations of HFrEF patients such as paediatric patients and patients with sleep apnoea.\(^\text{70,71}\)

---

**TABLE 3** Adverse effects in randomised controlled trials of sacubitril/valsartan, sodium-glucose cotransporter 2 inhibitors and vericiguat in heart failure

| Trial and drug          | Outcome                                      | Result                                      |
|-------------------------|----------------------------------------------|---------------------------------------------|
| PARADIGM-HF\(^\text{11}\) Sacubitril/valsartan | Stopped medication prematurely due to adverse effects | Sacubitril/valsartan group: 10.7% Enalapril group: 12.3% |
| PARAGON-HF\(^\text{32}\) Sacubitril/valsartan | Stopped medication prematurely due to adverse effects | Sacubitril/valsartan group: 25.3% Valsartan group: 26.7% |
| EMPEROR-Reduced\(^\text{12}\) Empagliflozin   | Stopped medication prematurely due to adverse effects | Empagliflozin group: 16.3% Placebo group: 18.0% |
| DAPA-HF\(^\text{13}\) Dapagliflozin            | Stopped medication prematurely due to adverse effects | Dapagliflozin group: 4.7% Placebo group: 4.9% |
| VICTORIA\(^\text{30}\) Vericiguat               | Serious adverse effects                       | Vericiguat group: 32.8% Placebo group: 34.8% |
the recommended therapy for symptomatic patients with HFrEF.\textsuperscript{12,13} The recommendations for SGLT2i treatment in HFrEF reflect the evidence from DAPA-HF and EMPEROR-Reduced.

EMPIRE-HF is investigating the effect on NT-proBNP levels of empagliflozin in HFrEF.\textsuperscript{76} The effects of SGLT2i should be investigated in stable patients with lower levels of natriuretic peptides.

### 4.1.3 | Vericiguat

In the VICTORIA trial, vericiguat showed a better effect than placebo in addition to recommended therapy in HFrEF when it comes to HHF or death from cardiovascular causes. The effect was independent of sacubitril/valsartan or enalapril treatment. The subpopulation with LVEF of 40\%–44\% did not reveal this effect. Moreover, there was no effect of vericiguat on death from any cause.\textsuperscript{50} A post hoc analysis of the VICTORIA trial investigated the effect of vericiguat in subgroups according to NT-proBNP levels. Vericiguat showed an effect in patients with NT-proBNP $\leq 8000$ pg/ml but showed no effect in patients with NT-proBNP $> 8000$ pg/ml.\textsuperscript{77}

The ACC and DSC do not recommend vericiguat for HFpEF patients.\textsuperscript{14,15} The ESC recommends to consider vericiguat in patients with worsening heart failure when treated with an ACEi or sacubitril/valsartan, a BAA and an MRA.\textsuperscript{1} The VICTORIA trial showed a significant effect of vericiguat on death from any cause.\textsuperscript{50} Inclusion of vericiguat should be considered in future recommendations reflecting the results from the VICTORIA trial.

Future studies should investigate the optimal dosage of vericiguat. At the present time, the highest dosage given in HFrEF is 10 mg once daily.\textsuperscript{50,78}

### 4.1.4 | Sacubitril/valsartan, sodium-glucose cotransporter 2 inhibitors and vericiguat: A comparison

The study populations in the PARADIGM-HF, DAPA-HF and EMPEROR-Reduced trials are comparable.\textsuperscript{11–13} The fact that the EMPEROR-Reduced trial did not show a significant effect on death from any cause could be attributable to less statistical power as the PARADIGM-HF trial had more participants and longer duration. The results suggested that sacubitril/valsartan had a more pronounced effect than SGLT2i in patients with LVEF $\geq 30\%$, but the effect of SGLT2i may be stronger than sacubitril/valsartan in the subpopulation with LVEF $< 30\%$. The comparison is arbitrary in the sense that sacubitril/valsartan involved the discontinuation of enalapril, whereas SGLT2i were given in addition to recommended treatment.

In the VICTORIA trial, vericiguat showed an effect in HFrEF.\textsuperscript{50} Unlike the studies on sacubitril/valsartan and SGLT2i, the VICTORIA trial included patients with LVEF of 40\%–44\%. The VICTORIA trial differed in other inclusion criteria as well and the duration was shorter. Generally, this makes it difficult to compare the effect of vericiguat to SGLT2i and sacubitril/valsartan. Current evidence suggests that sacubitril/valsartan and SGLT2i are beneficial in HFrEF compared with vericiguat.

It should be mentioned that both SGLT2i and vericiguat were effective in combination with sacubitril/valsartan in HFrEF.\textsuperscript{50,79}

### 4.2 | Heart failure with preserved ejection fraction

#### 4.2.1 | Sacubitril/valsartan

In the PARAGON-HF trial, sacubitril/valsartan did not show a better effect than valsartan on HHF or death from cardiovascular causes in patients with LVEF $\geq 45\%$. However, sacubitril/valsartan exerted a significant effect on the subpopulation with LVEF $< 57\%$ (lower median).\textsuperscript{32}

The ACC, ESC and DSC do not recommend sacubitril/valsartan for HFpEF patients.\textsuperscript{1,15,22} The recommendations reflect the results from the PARAGON-HF trial.\textsuperscript{32} Future studies and post hoc analyses from the PARAGON-HF trial should investigate the effect in certain subpopulations such as LVEF of 50\%–55\%.

#### 4.2.2 | Sodium-glucose cotransporter 2 inhibitors

The DECLARE-TIMI 58 trial did not show a significantly better effect of dapagliflozin than placebo on HHF or death from cardiovascular causes in patients with LVEF $\geq 45\%$ and type 2 diabetes.\textsuperscript{54} The SOLOIST-WHF trial demonstrated a significantly better effect of sotagliflozin than placebo on the primary endpoint, which was total number of deaths from cardiovascular causes and hospitalisations and urgent visits for heart failure in patients with LVEF $\geq 50\%$ and type 2 diabetes, but the rate of death from cardiovascular causes was not different.\textsuperscript{43} This can probably be ascribed to lack of power as the SOLOIST-WHF trial was terminated early due to lack of funding. These studies only included patients with type 2 diabetes. The EMPEROR-Preserved trial showed a better effect of empagliflozin than placebo
on HHF or death from cardiovascular causes independent of the diabetic status.\textsuperscript{57}

The ACC, ESC and DCS do not recommend SGLT2i for HFpEF patients.\textsuperscript{1,14,15} Evidence from the EMPEROR-Preserved trial suggests that empagliflozin should be initiated in patients with HFpEF.\textsuperscript{57} Currently, the DELIVER trial is focusing on the effect of dapagliflozin in HFpEF.\textsuperscript{80} The effect of SGLT2i is varying. This could be due to variation in diagnostic criteria, varying dosages or that the effect is only seen with specific SGLT2i and is not a drug class effect. Future studies should investigate these questions.

4.2.3 | Vericiguat

The VITALITY-HFpEF did not show a better effect of vericiguat than placebo on KCCQ PLS in patients with LVEF ≥ 45%.\textsuperscript{58}

Furthermore, the ACC, ESC and DCS do not recommend vericiguat for HFpEF treatment.\textsuperscript{1,15,22} This reflects current evidence and does not indicate an effect of vericiguat in HFpEF.

4.2.4 | Sacubitril/valsartan, sodium-glucose cotransporter 2 inhibitors and vericiguat: A comparison

Generally, the effects of sacubitril/valsartan, SGLT2i and vericiguat were not as well studied in HFpEF as in HFrEF. The PARAGON-HF trial demonstrated a better effect of sacubitril/valsartan than valsartan on HHF or death from cardiovascular causes in patients with LVEF of 45%–57% (lower median).\textsuperscript{32} Therefore, an RCT investigating the effect of sacubitril/valsartan in patients with LVEF of 40%–49% (HFmrEF) would be interesting.

Vericiguat is not well studied in patients with HFmrEF. In the VICTORIA trial, the subgroup of patients with LVEF of 40%–44% did not reveal a lower risk of HHF or death from cardiovascular causes.\textsuperscript{50} In the EMPEROR-Preserved trial, empagliflozin showed a significant effect on HHF or death from cardiovascular causes and empagliflozin is the only drug with compelling effect on HFmrEF.\textsuperscript{57} Currently, the DELIVER trial is investigating the effect of dapagliflozin in HFmrEF.\textsuperscript{80}

5 | LIMITATIONS

The clinical trials reviewed in this minireview are all listed in ClinicalTrials.gov and a major part of them are published in highly ranked journals. An important limit is the difficulty to generalise the results because the enrolled study patients are different from the patient population entering the health care system. In addition, being part of a clinical trial might influence the patients’ well-being and quality of life and thus influence the data. The current COVID-19 pandemic is a factor that have influenced enrolment and willingness of the patients to participate in studies running from February 2020. Another factor might be the compliance of the patients. Moreover, further analysis and clinical trials will be required to address whether sex, age and ethnicity play a role for the outcome of these drug classes.

The LIFE trial reported a smaller sample size and a relatively short duration compared with other phase 3 trials investigating NYHA class II to III heart failure patients. Moreover, the reasons for premature discontinuation of the study drug were not given. In addition, interpreting the findings of LIFE results needs a
discussion of how the COVID-19 mitigation strategy affected the results. The reduced number of enrolled patients from 400 to 335 can decrease the statistical power of the trial.\textsuperscript{67}

Finally, it should be taken into account that the majority of the international clinical studies are financed by pharmaceutical companies. The industry sponsorship of clinical trials can lead to important therapeutic advances, but the potential for bias in these studies may exist at multiple levels. Therefore, it is of high importance to recognize bias in clinical trials and to ensure objectivity in clinical research and that only drugs supported by unbiased, scientific evidence reach the market, clinic and finally the practicing doctors and patients.

6 | CONCLUSIONS

All three reviewed drug classes have mechanisms of action that could improve some of the pathophysiological imbalances presented in heart failure.

The three drug classes showed a positive effect in HFrEF. Current evidence suggests that sacubitril/valsartan and SGLT2i are more beneficial in HFrEF compared with vericiguat. The results suggested that sacubitril/valsartan had a more pronounced effect than SGLT2i in patients with LVEF \( \geq 30\% \), but the effect of SGLT2i may be more pronounced than sacubitril/valsartan in the subpopulation with LVEF \(<30\%\). However, lack of sufficient statistical power could be the reason for these differences. The comparison is arbitrary in the sense that sacubitril/valsartan involved discontinuation of enalapril, whereas SGLT2i and vericiguat were given in addition to recommended treatment. Both SGLT2i and vericiguat are shown to be effective in combination with sacubitril/valsartan in HFrEF.

Sacubitril/valsartan might be effective in HFpEF with LVEF of 50\%–55\%. The SGLT2i, empagliflozin, showed a compelling effect in HFpEF independent of the diabetic status. Vericiguat did not prove to be effective in HFpEF. It has to be taken into account that these treatments were not well studied. The comparison of the three drug classes in HFpEF was complicated by different inclusion criteria, population sizes and outcome measures.

Sacubitril/valsartan and SGLT2i, empagliflozin specifically, showed promising results in HFrEF. Vericiguat is not well studied in HFmrEF. The ACC and DSC do not have separate guidelines for HFmrEF.

The three drug classes could be a part of the therapy regimen in patients with congestive heart failure and should already be a part of the treatment among patients with reduced ejection fraction. Empagliflozin treatment should be considered for both HFmrEF and HFpEF. The effects vary between subpopulations.

Further studies need to be conducted to clarify the extent of effects in different subpopulations of patients with heart failure—especially in HFmrEF and HFpEF.

ACKNOWLEDGEMENTS

Ulf Simonsen has received funding from the Novo Nordisk Foundation (NNF20OC0065767). None of the funders have influenced the content of the manuscript.

CONFLICT OF INTEREST

Ulf Simonsen is consultant and owner of shares in Initiator Pharma A/S (https://www.initiatorpharma.com/en/). This article is not related to the profile or pipeline of this company. The authors report no conflicts of interest.

ORCID

Ulf Simonsen  © https://orcid.org/0000-0002-2169-7666

REFERENCES

1. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2021;42(36):3599-3726. doi: 10.1093/eurheartj/ehab368

2. Yusuf S, Pitt B, Davis CE, Hood WB, Cohn JN. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325(5):293-302. doi:10.1056/nejm199108013250501

3. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987;316:1429-1435. doi:10.1056/nejm198706043162301

4. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345(23):1667-1675. doi:10.1056/NEJMoa010713t

5. Granger CB, McMurray JJ, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet (London, England). 2003;362:772-776. doi: 10.1016/s0140-6736(03)14284-5

6. Packer M, Coats AJS, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001;345(22):1651-1658. doi:10.1056/nejm200105313442201

7. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet (London, England). 1999;353:2001-2007.

8. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet (London, England). 1999;353:9-13.
9. Zannad F, McMurray JVF, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. *N Engl J Med*. 2011;364(1):11-21. doi:10.1056/NEJMoa1009492

10. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. *N Engl J Med*. 1999;341(10):709-717. doi:10.1056/nejm19990923411001

11. McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. *N Engl J Med*. 2014;371(11):993-1004. doi:10.1056/NEJMoa1409077

12. Packer M, Anker SD, Butler J, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. *N Engl J Med*. 2020;383(15):1413-1424. doi:10.1056/NEJMoa2022190

13. McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. *N Engl J Med*. 2019;381(21):1995-2008. doi:10.1056/NEJMoa1911303

14. Maddox TM, Januzzi JL Jr, Allen LA, et al. Update to the 2017 ACC expert consensus decision pathway for optimization of heart failure treatment: answers to 10 pivotal issues about heart failure with reduced ejection fraction. *J Am Coll Cardiol*. 2021;77:772-810. doi:10.1016/j.jacc.2020.11.022

15. Kenneth Egstrup LK & Olav Wendelboe Nielsen Danish Society of Cardiology (DSC). Kronisk hjertesvigt. 2021. https://nbv.cardio.dk/chf

16. Cleland JG, Tendera M, Adamus J, et al. Irbesartan with or without placebo in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. *J Am Coll Cardiol*. 2003;362:777-781. doi:10.1016/S0735-1097(03)00428-1

17. Aronow WS, Ahn C, Kronzon I. Effect of propranolol versus no propranolol on total mortality plus nonfatal myocardial infarction in older patients with prior myocardial infarction, congestive heart failure, and left ventricular ejection fraction ≥40% treated with diuretics plus angiotensin-converting enzyme inhibitors. *Am J Cardiol*. 1997;80(2):207-209. doi:10.1016/s0002-9149(97)00320-2

18. Massie BM, Carson PE, McMurray JJ, et al. Irbesartan in patients with heart failure and preserved ejection fraction. *N Engl J Med*. 2008;359(23):2456-2467. doi:10.1056/NEJMoa0805450

19. Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. *Lancet (London, England)*. 2003;362:777-781. doi:10.1016/s0140-6736(03)12857-5

20. Pitt B, Pfeffer MA, Assmann SF, et al. Spironolactone for heart failure with preserved ejection fraction. *N Engl J Med*. 2014;370(15):1383-1392. doi:10.1056/NEJMoa1313731

21. Setaro JF, Zaret BL, Schulman DS, Black HR, Soufer R. Usefulness of verapamil for congestive heart failure associated with abnormal left ventricular diastolic filling and normal left ventricular systolic performance. *Am J Cardiol*. 1990;66(12):981-986. doi:10.1016/0002-9149(90)90937-v

22. Yancy CW, Jessup M, Bzozkurt B, et al. ACC/AHA/HPSA focused update of the 2013 ACC/AHA guideline for the management of heart failure. *J Am Coll Cardiol*. 2017;70:776-803. doi:10.1016/j.jacc.2017.04.025

23. Butler J, Yang M, Manzi MA, et al. Clinical course of patients with worsening heart failure with reduced ejection fraction. *J Am Coll Cardiol*. 2019;73(8):935-944. doi:10.1016/j.jacc.2018.11.049

24. Redfield M, Heart M. Failure with preserved ejection fraction. *N Engl J Med*. 2017;376(9):897-897. doi:10.1056/NEJMc1615918

25. Gu J, Noe A, Chandra P, et al. Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNI). *J Clin Pharmacol*. 2010;50(4):401-414. doi:10.1177/009127009343932

26. D’Elia E, Iacovoni A, Vaduganathan M, Lorini FL, Perlini S, Senni M. Neprilysin inhibition in heart failure: mechanisms and substrates beyond modulating natriuretic peptides. *Eur J Heart Fail*. 2017;19(6):710-717. doi:10.1002/ejhf.799

27. Martinez-Rumayor A, Richards AM, Burnett JC, Januzzi JL Jr. Biology of the natriuretic peptides. *Am J Cardiol*. 2008;101(3):3-8. doi:10.1016/j.amjcard.2007.11.012

28. Potter LR, Abbey-Hosch S, Dickey DM. Natriuretic peptides, their receptors, and cyclic guanosine monophosphate-dependent signaling functions. *Endocr Rev*. 2006;27(1):47-72. doi:10.1210/er.2005-0014

29. Gardner DG, Chen S, Glenn DJ, Grigsby CL. Molecular biology of the natriuretic peptide system: implications for physiology and hypotension. *Hypertension*. 2007;49(3):419-426. doi:10.1161/01.HYP.0000258532.07418.fa

30. Rutlopo LM, Dukat A, Böhm M, et al. Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study. *Lancet (London, England)*. 2010;375:1255-1266. doi:10.1016/s0140-6736(09)61966-8

31. Sacubitril/valsartan label FDA. 2021.

32. Solomon SD, McMurray JJ, Anand IS, et al. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. *N Engl J Med*. 2019;381(17):1609-1620. doi:10.1056/NEJMoa1908655

33. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. *N Engl J Med*. 2015;373(22):2117-2128. doi:10.1056/NEJMoa1504720

34. McMurray J. EMPA-REG—the “diuretic hypothesis”. *J Diabetes Complications*. 2016;30(1):3-4. doi:10.1016/j.jdiacomp.2015.10.012

35. Zanchi A, Burnier M, Muller ME, et al. Effects of SGLT2 inhibitor empagliflozin on renal sodium and glucose handling in patients with acute heart failure. *Am J Cardiol*. 2014;114(6):68-78. doi:10.1016/j.amjcard.2013.11.028

36. Norrie J, Hulbert-Shearon RE, Januzzi JL Jr, et al. Diuretic and nondiuretic heart failure hospitalization: a randomized, placebo-controlled trial. *J Heart Fail*. 2020;8(2):219-230. doi:10.1016/j.jhf.2019.03.006
38. Nassif ME, Windsor SL, Tang F, et al. Dapagliflozin effects on lung fluid volumes in patients with heart failure and reduced ejection fraction: results from the DEFINE-HF trial. *Diabetes Obes Metab*. 2021;23(6):1426-1430. doi: 10.1111/dom.14352

39. Santos-Gallogo CG, Vargas-Delgado AP, Requena-Ibanez JA, et al. Randomized trial of empagliflozin in nondiabetic patients with heart failure and reduced ejection fraction. *J Am Coll Cardiol*. 2021;77(3):243-255. doi:10.1016/j.jacc.2020.11.008

40. Canagliflozin label FDA. 2018.

41. Dapagliflozin label FDA. 2020.

42. Empagliflozin label FDA. 2020.

43. Bhatt DL, Szarek M, Steg PG, et al. Sotagliflozin in patients with diabetes and recent worsening heart failure. *N Engl J Med*. 2021;384(2):117-128. doi:10.1056/NEJMoa2030183

44. Bryan NS, Bian K, Murad F. Discovery of the nitric oxide signaling pathway and targets for drug development. *Front Biosci (Landmark Ed)*. 2009;14:1-18. doi:10.2741/3228

45. Mitrovic V, Hernandez AF, Meyer M, Gheorghiade M. Role of guanylate cyclase modulators in decompensated heart failure. *Heart Fail Rev*. 2009;14(4):309-319. doi:10.1007/s10741-009-9149-7

46. Paulus WJ, Bronzwaer JG. Nitric oxide’s role in the heart: control of beating or breathing? *Am J Physiol Heart Circ Physiol*. 2004;287(1):H8-H13. doi:10.1152/ajpheart.01147.2003

47. Varin R, Mulder P, Tamion F, et al. Improvement of endothelial function by chronic angiotensin-converting enzyme inhibition in heart failure: role of nitric oxide, prostanoids, oxidant stress, and Bradykinin. *Circulation*. 2000;102(3):351-356. doi:10.1161/01.CIR.102.3.351

48. Boerrigter G, Costello-Boerrigter LC, Cataliotti A, et al. Cardiorenal and humoral properties of a novel direct soluble guanylate cyclase stimulator BAY 41-2272 in experimental congestive heart failure. *Circulation*. 2003;107(5):686-689. doi:10.1161/01.cir.0000057373.15443.f8

49. Vericiguat label FDA. 2021.

50. Armstrong PW, Pieske B, Anstrom KJ, et al. Vericiguat in patients with heart failure and reduced ejection fraction. *N Engl J Med*. 2020;382(20):1883-1893. doi:10.1056/NEJMoa1915928

51. Lombardi CM, Cimino G, Pagnesi M, et al. Vericiguat for heart failure with reduced ejection fraction. *Curr Cardiol Rep*. 2021;23(10):144. doi:10.1007/s11886-021-01580-6

52. Mascolo A, Scavone C, Scisciola L, et al. SGLT-2 inhibitors reduce the risk of cerebrovascular/cardiovascular outcomes and mortality: a systematic review and meta-analysis of retrospective cohort studies. *Pharmacol Res*. 2021;172:105836. doi:10.1016/j.phrs.2021.105836

53. Wehland M, Simonsen U, Buus NH, Krüger M, Grimm D. An evaluation of the fixed-dose combination sacubitril/valsartan for the treatment of arterial hypertension. *Expert Opin Pharmacother*. 2020;21(10):1133-1143. doi:10.1080/14656566.2020.1735536

54. Kato ET, Silverman MG, Mosenzon O, et al. Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus. *Circulation*. 2019;139(22):2528-2536. doi:10.1161/circulationaha.119.040130

55. Cosentino F, Cannon CP, Cherney DZI, et al. Efficacy of ertugliflozin on heart failure-related events in patients with type 2 diabetes mellitus and established atherosclerotic cardiovascular disease: results of the VERITIS CV trial. *Circulation*. 2020;142(23):2205-2215. doi:10.1161/circulationaha.120.050255

56. Solomon SD, Zile M, Pieske B, et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. *Lancet*. (London, England). 2012;380:1387-1395. doi:10.1016/s0140-6736(12)62227-6

57. Anker SD, Butler J, Filippatos G, et al. Empagliflozin in heart failure with a preserved ejection fraction. *N Engl J Med*. 2021;385(16):1451-1461. doi:10.1056/NEJMoa2107038

58. Armstrong PW, Lam CSP, Anstrom KJ, et al. Effect of vericiguat vs placebo on quality of life in patients with heart failure and preserved ejection fraction: the VITALITY-HFpEF randomized clinical trial. *JAMA*. 2020;324(15):1512-1521. doi:10.1001/jama.2020.15922

59. Lewis EF, Claggett BL, McMurray JJ, et al. Health-related quality of life outcomes in PARADIGM-HF. *Circ Heart Fail*. 2017;10:e003430. doi:10.1161/circheartfailure.116.003430

60. Balmforth C, Simpson J, Shen L, et al. Outcomes and effect of treatment according to etiology in HFReF: an analysis of PARADIGM-HF. *JACC Heart Fail*. 2019;7(6):457-465. doi:10.1016/j.jchf.2019.02.015

61. Böhmer M, Young R, Jhund PS, et al. Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF. *Eur Heart J*. 2017;38(15):1132-1143. doi:10.1093/eurheartj/ehw570

62. Vardeny O, Claggett B, Packer M, et al. Efficacy of sacubitril/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM-HF trial. *Eur J Heart Fail*. 2016;18(10):1228-1234. doi:10.1002/ejhf.580

63. Okumura N, Jhund PS, Gong J, et al. Effects of sacubitril/valsartan in the PARADIGM-HF trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) according to background therapy. *Circ Heart Fail*. 2016;9:e003212. doi:10.1161/circheartfailure.116.003212

64. Jhund PS, Fuh M, Bayram E, et al. Efficacy and safety of LCZ696 (sacubitril-valsartan) according to age: insights from PARADIGM-HF. *Eur Heart J*. 2015;36(38):2576-2584. doi:10.1093/eurheartj/ehv330

65. Simpson J, Jhund PS, Silva Cardoso J, et al. Comparing LCZ696 with enalapril according to baseline risk using the MAGGIC and EMPHASIS-HF risk scores: an analysis of mortality and morbidity in PARADIGM-HF. *J Am Coll Cardiol*. 2015;66(19):2059-2071. doi:10.1016/j.jacc.2015.08.878

66. Morrow DA, Velazquez EJ, DeVore AD, et al. Clinical outcomes in patients with acute decompensated heart failure randomly assigned to sacubitril/valsartan or enalapril in the PIONEER-HF trial. *Circulation*. 2019;139(19):2285-2288. doi:10.1161/circulationaha.118.039331

67. Mann DL, Givertz MM, Vadera JM, et al. Effect of treatment with sacubitril/valsartan in patients with advanced heart failure and reduced ejection fraction: a randomized clinical
68. Senni M, McMurray JJ, Wachter R, et al. Initiating sacubitril/valsartan (LCZ696) in heart failure: results of TITRATION, a double-blind, randomized comparison of two uptitration regimens. *Eur J Heart Fail.* 2016;18:1193-1202. doi: 10.1002/ejhf.548

69. Tsutsui H, Momomura SI, Saito Y, et al. Angiotensin receptor neprilysin inhibitor in Japanese patients with heart failure and reduced ejection fraction—baseline characteristics and treatment of PARALLEL-HF trial. *Circ J.* 2018;82:2575-2583. doi: 10.1253/circj.CJ-17-1424

70. Jaffuel D, Molinari N, Berdague P, et al. Impact of sacubitril-valsartan combination in patients with chronic heart failure and sleep apnoea syndrome: the ENTRESTO-SAS study design. *ESC Heart Fail.* 2018;5(3):222-230. doi: 10.1002/ehf2.12270

71. Shaddy R, Canter C, Halnon N, et al. Design for the sacubitril/valsartan (LCZ696) compared with enalapril study of pediatric patients with heart failure due to systemic left ventricle systolic dysfunction (PANORAMA-HF study). *Am Heart J.* 2017;193:23-34. doi:10.1016/j.ahj.2017.07.006

72. Butler J, Anker SD, Filippatos G, et al. Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial. *Eur Heart J.* 2021;42(13):1203-1212. doi:10.1093/eurheartj/ehaa1007

73. Kosiborod MN, Jhund PS, Docherty KF, et al. Effects of dapagliflozin on symptoms, function, and quality of life in patients with heart failure and reduced ejection fraction: results from the DAPA-HF trial. *Circulation.* 2020;141(2):90-99. doi:10.1161/circulationaha.119.044138

74. Petrie MC, Verma S, Docherty KF, et al. Effect of dapagliflozin on worsening heart failure and cardiovascular death in patients with heart failure with and without diabetes. *JAMA.* 2020;323(14):1353-1368. doi:10.1001/jama.2020.1906

75. Martinez FA, Serenelli M, Nicolau JC, et al. Efficacy and safety of dapagliflozin in heart failure with reduced ejection fraction according to age: insights from DAPA-HF. *Circulation.* 2020;141(2):100-111. doi:10.1161/circulationaha.119.044133

76. Jensen J, Omar M, Kistorp C, et al. Empagliflozin in heart failure patients with reduced ejection fraction: a randomized clinical trial (Empire HF). *Trials.* 2019;20(1):374. doi: 10.1186/s13063-019-3474-5

77. Ezekowitz JA, O’Connor CM, Troughton RW, et al. N-terminal pro-B-type natriuretic peptide and clinical outcomes: vericiguat heart failure with reduced ejection fraction study. *JACC Heart Fail.* 2020;8(11):931-939. doi:10.1016/j.jchf.2020.08.008

78. Gheorghiade M, Greene SJ, Butler J, et al. Effect of vericiguat, a soluble guanylate cyclase stimulator, on natriuretic peptide levels in patients with worsening chronic heart failure and reduced ejection fraction: the SOCRATES-REDUCED randomized trial. *JAMA.* 2015;314(21):2251-2262. doi:10.1001/jama.2015.15734

79. Packer M, Anker SD, Butler J, et al. Influence of neprilysin inhibition on the efficacy and safety of empagliflozin in patients with chronic heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial. *Eur Heart J.* 2021;42(6):671-680. doi:10.1093/eurheartj/ehaa968

80. Solomon SD, Boer RA, DeMets D, et al. Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial. *Eur J Heart Fail.* 2021;23(7):1217-1225. doi:10.1002/ejhf.2249

**How to cite this article:** Norre T, Grimm D, Simonsen U. Sacubitril/valsartan, sodium-glucose cotransporter 2 inhibitors and vericiguat for congestive heart failure therapy. *Basic Clin Pharmacol Toxicol.* 2022;130(4):425-438. doi:10.1111/bcpt.13714